Cancer Drug Development Roundtable at Ohio State, May 4, 2011

On Wednesday, May 4, a team of leaders in cancer research, the pharmaceutical industry and from federal regulatory agencies as well as third-party cancer organizations met to develop recommendations that will facilitate future collaborations for the co-development of two or more investigational drugs.

To view videos of the public session of the Cancer Drug Development Roundtable please click on one of the links below:
Part 1
Part 2
Part 3
Part 4
Part 5
Part 6

To view the PowerPoint slides from the public session, please click
here.

Speakers included:

• U.S. Food and Drug Administration: Janet Woodcock, MD, Director, Center for Drug Evaluation and Research
• National Cancer Institute: James Doroshow, MD, Director, Division of Cancer Treatment and Diagnosis
• Industry: Eric Rubin, MD, Vice President, Oncology Clinical Research, Merck
• Ohio State: Michael Caligiuri, MD, Director, The Ohio State University Comprehensive Cancer Center and CEO, James Cancer Hospital and Solove Research Institute


To view Dr. Michael Caligiuri's recent blog post about the Roundtable, please click
here.


            

 

 

Below is a video featuring Bhuvaneswari Ramaswamy, MD, a Medical Oncologist and one of Ohio State's leading physician-researchers, who discusses the importance of solving this drug development issue:

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 460 W. 10th Avenue, Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu